Xilio Therapeutics, Inc.
XLOHealthcare|Biotechnology|US
$8.62
+0.12 (+1.41%)
DCF Value
$329.92
Tangible Book / Share
$3.72
Cash / Share
$7.01
Ownership Breakdown
35.8%
Float
6.6M
Shares Outstanding
2.4M
Float Shares
Major Holders (35)
Combined: 220.0%
Holders of 5%+ from their latest Schedule 13D/13G filing in the last two years. Percentages are as of each filing date.
| Holder | Type | % of Class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Corporation | 19.90% | 14,517,678 | Feb 12, 2026 | 13D/G |
| Gilead Sciences Inc | Corporation | 19.90% | 9,105,451 | Dec 19, 2024 | 13D/G |
| Orbimed Advisors LLC | Investment adviser | 9.99% | 642,000 | May 15, 2026 | 13D/G |
| BCLS II Equity Opportunities, LP | Partnership | 9.99% | 664,021 | May 15, 2026 | 13D/G |
| Coastlands Capital GP LLC | Other | 9.99% | 5,346,069 | Dec 11, 2025 | 13D/G |
| Coastlands Capital Partners LP | Partnership | 9.99% | 5,346,069 | Dec 11, 2025 | 13D/G |
| Coastlands Capital LP | IA, PN | 9.99% | 5,346,069 | Dec 11, 2025 | 13D/G |
| Matthew D. Perry | HC, IN | 9.99% | 5,346,069 | Dec 11, 2025 | 13D/G |
| Coastlands Capital LLC | HC, OO | 9.99% | 5,346,069 | Dec 11, 2025 | 13D/G |
| Sirenia Capital Management LP | IA, PN | 9.90% | 1,142,862 | May 15, 2026 | 13D/G |
| Alex Silverstein | HC, IN | 9.90% | 1,142,862 | May 15, 2026 | 13D/G |
| StemPoint Capital Management GP LLC | Other | 9.50% | 628,866 | Aug 14, 2026 | 13D/G |
| Michelle Ross | HC, IN | 9.50% | 628,866 | Aug 14, 2026 | 13D/G |
| StemPoint Capital LP | IA, PN | 9.50% | 628,866 | Aug 14, 2026 | 13D/G |
| AbbVie Inc. | Corporation | 9.00% | 4,347,826 | Feb 18, 2025 | 13D/G |
| OrbiMed Capital GP X LLC | Other | 7.49% | 481,500 | May 15, 2026 | 13D/G |
| Frazier Life Sciences Public Fund, L.P. | Partnership | 6.70% | 4,676,472 | Feb 13, 2026 | 13D/G |
| FHMLSP, L.L.C. | Other | 6.70% | 4,676,472 | Feb 13, 2026 | 13D/G |
| FHMLSP, L.P. | Partnership | 6.70% | 4,676,472 | Feb 13, 2026 | 13D/G |
| Frazier Life Sciences Public Overage Fund, L.P. | Partnership | 4.40% | 2,401,633 | Aug 14, 2025 | 13D/G |
| FHMLSP Overage, L.P. | Partnership | 4.40% | 2,401,633 | Aug 14, 2025 | 13D/G |
| FHMLSP Overage, L.L.C. | Other | 4.40% | 2,401,633 | Aug 14, 2025 | 13D/G |
| Abigail P. Johnson | Individual | 3.17% | 1,395,853 | Nov 12, 2024 | 13D/G |
| FMR LLC | Holding company | 3.17% | 1,395,853 | Nov 12, 2024 | 13D/G |
| Frazier Life Sciences XII, L.P. | Partnership | 1.00% | 692,657 | Feb 13, 2026 | 13D/G |
| FHMLS Xii, L.P. | Partnership | 1.00% | 692,657 | Feb 13, 2026 | 13D/G |
| FHMLS Xii, L.L.C. | Other | 1.00% | 692,657 | Feb 13, 2026 | 13D/G |
| Frazier Life Sciences XI, L.P. | Partnership | 0.60% | 396,902 | Feb 13, 2026 | 13D/G |
| FHMLS XI, L.L.C. | Other | 0.60% | 396,902 | Feb 13, 2026 | 13D/G |
| FHMLS XI, L.P. | Partnership | 0.60% | 396,902 | Feb 13, 2026 | 13D/G |
| Patrick J. Heron | Individual | 0.20% | 149,060 | Feb 13, 2026 | 13D/G |
| FHMLS X, L.L.C. | Other | 0.20% | 149,060 | Feb 13, 2026 | 13D/G |
| FHMLS X, L.P. | Partnership | 0.20% | 149,060 | Feb 13, 2026 | 13D/G |
| Frazier Life Sciences X, L.P. | Partnership | 0.20% | 149,060 | Feb 13, 2026 | 13D/G |
| James N. Topper | Individual | 0.20% | 149,060 | Feb 13, 2026 | 13D/G |
Insider Trades (100)
Last 4 quarters: 3,979,250 acquired · 94,106 disposed
| Insider | Position | Date | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Houvras Yariv | CHIEF MEDICAL OFFICER | Oct 1, 2026 | AWARD | 105,000 | $8.91 | $935.5K | Form 4 |
| Houvras Yariv | Sep 28, 2026 | OTHER | 0 | — | — | Form 4 | |
| Bello Akintunde Olatokumbo | director | Jun 11, 2026 | AWARD | 5,000 | $7.99 | $40.0K | Form 4 |
| Shannon James Samuel | director | Jun 11, 2026 | AWARD | 5,000 | $7.99 | $40.0K | Form 4 |
| Curran Daniel J. | director | Jun 11, 2026 | AWARD | 5,000 | $7.99 | $40.0K | Form 4 |
| Xu Yuan | director | Jun 11, 2026 | AWARD | 5,000 | $7.99 | $40.0K | Form 4 |
| ROSS ROBERT W. | director | Jun 11, 2026 | AWARD | 5,000 | $7.99 | $40.0K | Form 4 |
| Bonstein Sara | director | Jun 11, 2026 | AWARD | 5,000 | $7.99 | $40.0K | Form 4 |
| Brennan Aoife | director | Jun 11, 2026 | AWARD | 5,000 | $7.99 | $40.0K | Form 4 |
| Blanchard Cheryl R | director | Apr 15, 2026 | AWARD | 10,000 | $8.40 | $84.0K | Form 4 |
| Blanchard Cheryl R | Apr 15, 2026 | OTHER | 0 | — | — | Form 4 | |
| Shannon James Samuel | director | Mar 26, 2026 | BUY | 5,000 | $8.79 | $43.9K | Form 4 |
| GILEAD SCIENCES, INC. | 10 percent owner | Feb 13, 2026 | BUY | 3,739,000 | $0.00 | $373.90 | Form 4 |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | Dec 31, 2025 | AWARD | 451,885 | $0.84 | $380.0K | Form 4 |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | Jan 1, 2026 | OPTION EX. | 16,625 | — | — | Form 4 |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | Jan 1, 2026 | OPTION EX. | 16,625 | — | — | Form 4 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Dec 31, 2025 | AWARD | 95,221 | $0.84 | $80.1K | Form 4 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Jan 1, 2026 | OPTION EX. | 5,000 | — | — | Form 4 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Jan 1, 2026 | OPTION EX. | 5,000 | — | — | Form 4 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Jan 2, 2026 | SELL | 1,826 | $0.64 | $1.2K | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Dec 31, 2025 | AWARD | 668,789 | $0.84 | $562.5K | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Jan 1, 2026 | OPTION EX. | 19,375 | — | — | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Jan 1, 2026 | OPTION EX. | 19,375 | — | — | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Jan 2, 2026 | SELL | 7,030 | $0.64 | $4.5K | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Dec 31, 2025 | AWARD | 1,500,258 | $0.84 | $1.3M | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Jan 1, 2026 | OPTION EX. | 44,250 | — | — | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Jan 1, 2026 | OPTION EX. | 44,250 | — | — | Form 4 |
| GILEAD SCIENCES, INC. | 10 percent owner | Nov 26, 2025 | X | 13,335,000 | $0.00 | $1.3K | Form 4 |
| GILEAD SCIENCES, INC. | 10 percent owner | Nov 26, 2025 | DISPOSED | 13,335,000 | $0.75 | $10.0M | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Nov 21, 2025 | AWARD | 925,000 | $0.84 | $777.9K | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Nov 21, 2025 | AWARD | 300,000 | $1.50 | $450.0K | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Nov 21, 2025 | AWARD | 155,090 | $1.50 | $232.6K | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Nov 21, 2025 | AWARD | 150,000 | $1.50 | $225.0K | Form 4 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Nov 21, 2025 | AWARD | 131,700 | $0.84 | $110.8K | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Nov 21, 2025 | AWARD | 117,000 | $1.50 | $175.5K | Form 4 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Nov 21, 2025 | AWARD | 55,000 | $1.00 | $55.0K | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Nov 21, 2025 | AWARD | 45,000 | $1.50 | $67.5K | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Nov 21, 2025 | AWARD | 37,296 | $1.50 | $55.9K | Form 4 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Nov 21, 2025 | AWARD | 25,000 | $1.00 | $25.0K | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Nov 21, 2025 | AWARD | 23,786 | $1.50 | $35.7K | Form 4 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Nov 21, 2025 | AWARD | 20,000 | $1.00 | $20.0K | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Nov 21, 2025 | AWARD | 20,000 | $1.50 | $30.0K | Form 4 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Nov 21, 2025 | DISPOSED | 55,000 | $3.17 | $174.3K | Form 4 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Nov 21, 2025 | DISPOSED | 25,000 | $2.79 | $69.6K | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Nov 21, 2025 | DISPOSED | 300,000 | $2.79 | $835.5K | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Nov 21, 2025 | DISPOSED | 117,000 | $2.69 | $314.7K | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Nov 21, 2025 | DISPOSED | 37,296 | $16.00 | $596.7K | Form 4 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Nov 21, 2025 | DISPOSED | 20,000 | $1.08 | $21.6K | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Nov 21, 2025 | DISPOSED | 20,000 | $2.13 | $42.6K | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Nov 21, 2025 | DISPOSED | 45,000 | $12.66 | $569.7K | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Nov 21, 2025 | DISPOSED | 150,000 | $2.75 | $412.5K | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Nov 21, 2025 | DISPOSED | 23,786 | $6.65 | $158.2K | Form 4 |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | Nov 21, 2025 | AWARD | 625,000 | $0.84 | $525.6K | Form 4 |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | Nov 21, 2025 | AWARD | 106,000 | $1.50 | $159.0K | Form 4 |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | Nov 21, 2025 | AWARD | 44,210 | $1.50 | $66.3K | Form 4 |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | Nov 21, 2025 | AWARD | 35,000 | $1.50 | $52.5K | Form 4 |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | Nov 21, 2025 | AWARD | 25,000 | $1.50 | $37.5K | Form 4 |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | Nov 21, 2025 | AWARD | 15,000 | $1.50 | $22.5K | Form 4 |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | Nov 21, 2025 | DISPOSED | 106,000 | $2.79 | $295.7K | Form 4 |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | Nov 21, 2025 | DISPOSED | 44,210 | $9.69 | $428.4K | Form 4 |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | Nov 21, 2025 | DISPOSED | 15,000 | $2.37 | $35.5K | Form 4 |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | Nov 21, 2025 | DISPOSED | 35,000 | $2.69 | $94.2K | Form 4 |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | Nov 21, 2025 | DISPOSED | 25,000 | $2.79 | $69.6K | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Nov 21, 2025 | AWARD | 2,075,000 | $0.84 | $1.7M | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Nov 21, 2025 | AWARD | 700,000 | $1.50 | $1.1M | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Nov 21, 2025 | AWARD | 473,334 | $1.50 | $710.0K | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Nov 21, 2025 | AWARD | 350,000 | $1.50 | $525.0K | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Nov 21, 2025 | AWARD | 239,703 | $1.50 | $359.6K | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Nov 21, 2025 | AWARD | 150,000 | $1.50 | $225.0K | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Nov 21, 2025 | AWARD | 135,134 | $1.50 | $202.7K | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Nov 21, 2025 | AWARD | 100,000 | $1.50 | $150.0K | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Nov 21, 2025 | AWARD | 50,041 | $1.50 | $75.1K | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Nov 21, 2025 | DISPOSED | 150,000 | $12.66 | $1.9M | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Nov 21, 2025 | DISPOSED | 100,000 | $13.83 | $1.4M | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Nov 21, 2025 | DISPOSED | 700,000 | $2.79 | $1.9M | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Nov 21, 2025 | DISPOSED | 239,703 | $5.51 | $1.3M | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Nov 21, 2025 | DISPOSED | 473,334 | $5.89 | $2.8M | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Nov 21, 2025 | DISPOSED | 50,041 | $16.00 | $800.7K | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Nov 21, 2025 | DISPOSED | 350,000 | $2.69 | $941.5K | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Nov 21, 2025 | DISPOSED | 135,134 | $11.69 | $1.6M | Form 4 |
| Shannon James Samuel | director | Jun 17, 2025 | BUY | 25,000 | $0.69 | $17.2K | Form 4 |
| Shannon James Samuel | director | Jun 16, 2025 | BUY | 45,000 | $0.69 | $30.9K | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Jun 16, 2025 | BUY | 36,289 | $0.68 | $24.7K | Form 4 |
| Russo Rene | Jan 1, 2025 | OTHER | 0 | — | — | Form 4 | |
| ROSS ROBERT W. | director | Jun 11, 2025 | AWARD | 31,000 | $0.69 | $21.5K | Form 4 |
| Brennan Aoife | director | Jun 11, 2025 | AWARD | 31,000 | $0.69 | $21.5K | Form 4 |
| Bonstein Sara | director | Jun 11, 2025 | AWARD | 31,000 | $0.69 | $21.5K | Form 4 |
| Curran Daniel J. | director | Jun 11, 2025 | AWARD | 31,000 | $0.69 | $21.5K | Form 4 |
| Clancy Paul J | director | Jun 11, 2025 | AWARD | 31,000 | $0.69 | $21.5K | Form 4 |
| Xu Yuan | director | Jun 11, 2025 | AWARD | 31,000 | $0.69 | $21.5K | Form 4 |
| Shannon James Samuel | director | Jun 11, 2025 | AWARD | 31,000 | $0.69 | $21.5K | Form 4 |
| Rossi Christina | director | Jun 11, 2025 | AWARD | 31,000 | $0.69 | $21.5K | Form 4 |
| Bello Akintunde Olatokumbo | director | Jun 10, 2025 | AWARD | 62,000 | $0.70 | $43.4K | Form 4 |
| Bello Akintunde Olatokumbo | Jun 10, 2025 | OTHER | 0 | — | — | Form 4 | |
| GILEAD SCIENCES, INC. | 10 percent owner | Jun 5, 2025 | BUY | 13,335,000 | $0.00 | $1.3K | Form 4 |
| GILEAD SCIENCES, INC. | 10 percent owner | Jun 5, 2025 | BUY | 13,335,000 | $0.75 | $10.0M | Form 4 |
| GILEAD SCIENCES, INC. | 10 percent owner | Jun 5, 2025 | BUY | 13,335,000 | $0.75 | $10.0M | Form 4 |
| GILEAD SCIENCES, INC. | 10 percent owner | Jun 5, 2025 | BUY | 13,335,000 | $0.75 | $10.0M | Form 4 |
| Russo Rene | director, officer: PRESIDENT AND CEO | Apr 15, 2025 | AWARD | 190,000 | $0.71 | $135.3K | Form 4 |
| Frankenfield Christopher James | Chief Financial Officer | Apr 15, 2025 | AWARD | 75,000 | $0.71 | $53.4K | Form 4 |